Press release content from PR Newswire. The AP news staff was not involved in its creation.
VLP Therapeutics raises $16M Series A for cancer treatment vaccine R&D
March 15, 2021 GMT
Logo of VLP Therapeutics
GAITHERSBURG, Md., March 15, 2021 /PRNewswire/ -- US-based biotech company VLP Therapeutics, Inc. (VLPT) announced on March 15 that it has raised US$16 million in a Series A funding round from MIYAKO Capital Co., Ltd., Sojitz Corporation, Konishiyasu Co., Ltd., in Japan and three existing investors in the US (Mr. Robert G. Hisaoka, SK Impact Fund, LLC, and RJ Fund, LLC) for research and development of a cancer treatment vaccine. With this funding, VLPT aims to accelerate the project well underway in the US and move into clinical trials at the earliest date possible.